

Holista enters into a Joint Venture with GICC for the production of M3[®] HVAC systems for all markets outside North America

2 SEPTEMBER 2020

ASX Announcement

Holista Colltech Limited (ASX: HCT, “Holista”) is pleased to announce that it has entered into a non binding collaboration term sheet (Agreement) for a joint-venture (JV) with Global Infection Control Consultants LLC (GICC) to pursue opportunities for the M3[®] system outside of North America. A formal agreement between GICC and Holista will be subsequently put in place.

The M3[®] system works by dispensing Path-Away[®] through heating, ventilation and air-conditioning (“HVAC”) systems to treat harmful pathogens, including air borne viruses. The system can measure, monitor and contain airborne (aerosol) viruses, pathogens and other biological contaminants.

Path-Away[®] is a plant-based active ingredient developed by GICC, which contains no chemicals or alcohol.

A Singapore-based manufacturing JV will be formed, which will be 49% owned by Holista and 51% owned by GICC. The JV will hold the rights to manufacture the M3[®] system for markets outside North America. There will be minimal capital investment required by Holista as the JV will outsource all manufacturing as orders are received. The manufacturer is yet to be appointed by the JV. Operational expenses including the establishment of an outsourced marketing functions are to be absorbed by the existing administration budget. There will be no direct financial impact on Holista.

The JV Agreement follows GICC’s success at securing a 36-month contract with the United States government to manufacture and install up to 10 million of its M3[®] systems to disinfect large buildings. Holista and the JV are not part of GICC’s US contract.

“The GICC-Holista JV agreement builds on the strong working relationship that already exists between the two companies. This JV also allows the M3[®] system to be available for markets outside North America” said Dr Arthur V. Martin, President of GICC.

“We are excited to be partnering with Holista to offer our proven M3[®] solution in other key markets given that HVAC’s are a known for spreading viruses.”

Dr. Rajen Manicka, Chief Executive Officer of Holista, said: “The JV creates a new and significant opportunity for us to use Path-Away[®] in a large-scale industrial application for the first time. The M3[®] system complements our existing range of

products, including our all-natural NatShield™ hand sanitiser that uses Path-Away® as an active ingredient to kill a broad spectrum of microbes.”

As announced previously by Holista, Path-Away® was successfully tested in April 2020 by a leading U.K. bio-safety laboratory. The tests confirmed Path-Away® to be 99.99% effective within one minute of use on the feline coronavirus, a recognised surrogate of SARS-CoV-2.

GICC and Holista have commenced additional tests at the Microbac Laboratories in Virginia, which is approved by the US Center for Diseases Control (“CDC”), on the human COVID-19 strain. The final audited test results are expected to be released in October 2020.

This announcement has been approved for release by all members of the Holista Board.

About Holista Colltech Ltd

Holista CollTech Ltd(“Holista”) is a natural wellness company, that has the following main divisions:

- Dietary supplements
- Food Ingredients
- Ovine collagen
- Infection Control Solutions

Holista has a global collaboration with Global Infection Control Consultants LLC to use Path-Away® a plant-based solution that is proven to kill a board spectrum of microbes. The all-natural alcohol-free active ingredient is used in Holista’s range of sanitising products under the NatShield™ brand.

Listed on the Australian Securities Exchange (“ASX”), Holista researches, develops, manufactures and markets health style products. Holista’s suite of ingredients includes low GI baked products, reduced sodium salts, low fat fried foods and low calorie sugar without compromising taste, odour and mouthfeel. Holista also produces sheep (ovine) collagen using patented extraction methods.

For further information, please contact:

Corporate Affairs & Business Opportunities

Corporate Matters: investor@holistaco.com

General Enquiries: enquiries@holistaco.com

Australia

Level 5, 126 Phillip Street,
Sydney, NSW 2000
P: 02 8072 1400; F: 02 8072 1440

Malaysia

12th Floor, Amcorp Trade Centre, PJ Tower
No. 18, Persiaran Barat off Jalan Timur
46000, Petaling Jaya, Malaysia
P: +603 7965 2828 ; F: +603 7965 2777

Australia and New Zealand Investor relations and media enquiries:

Brendon Lau, Vantage Point Partners
E: brendon@vantagepointpartners.com.au
M: +61 409 341 613

Global Investor relations and media enquiries:

WeR1 Consultants Pte Ltd
E: holista@wer1.net
M: +65 673 74 844